Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1950 1
1964 1
1966 1
1970 1
1972 1
1974 1
1976 2
1978 3
1979 2
1981 3
1983 3
1984 2
1985 1
1986 1
1987 3
1989 3
1990 1
1992 4
1993 2
1994 1
1995 3
1996 2
1998 2
1999 2
2000 1
2001 2
2002 1
2003 2
2004 4
2005 3
2006 4
2007 1
2008 3
2009 8
2010 6
2011 4
2012 5
2013 4
2014 4
2015 7
2016 2
2017 6
2018 11
2019 13
2020 8
2021 17
2022 10
2023 14
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

174 results

Results by year

Filters applied: . Clear all
Page 1
Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer.
Makker V, Colombo N, Casado Herráez A, Santin AD, Colomba E, Miller DS, Fujiwara K, Pignata S, Baron-Hay S, Ray-Coquard I, Shapira-Frommer R, Ushijima K, Sakata J, Yonemori K, Kim YM, Guerra EM, Sanli UA, McCormack MM, Smith AD, Keefe S, Bird S, Dutta L, Orlowski RJ, Lorusso D; Study 309–KEYNOTE-775 Investigators. Makker V, et al. N Engl J Med. 2022 Feb 3;386(5):437-448. doi: 10.1056/NEJMoa2108330. Epub 2022 Jan 19. N Engl J Med. 2022. PMID: 35045221 Clinical Trial.
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial.
Mok TSK, Wu YL, Kudaba I, Kowalski DM, Cho BC, Turna HZ, Castro G Jr, Srimuninnimit V, Laktionov KK, Bondarenko I, Kubota K, Lubiniecki GM, Zhang J, Kush D, Lopes G; KEYNOTE-042 Investigators. Mok TSK, et al. Lancet. 2019 May 4;393(10183):1819-1830. doi: 10.1016/S0140-6736(18)32409-7. Epub 2019 Apr 4. Lancet. 2019. PMID: 30955977 Clinical Trial.
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study.
Cohen EEW, Soulières D, Le Tourneau C, Dinis J, Licitra L, Ahn MJ, Soria A, Machiels JP, Mach N, Mehra R, Burtness B, Zhang P, Cheng J, Swaby RF, Harrington KJ; KEYNOTE-040 investigators. Cohen EEW, et al. Lancet. 2019 Jan 12;393(10167):156-167. doi: 10.1016/S0140-6736(18)31999-8. Epub 2018 Nov 30. Lancet. 2019. PMID: 30509740 Clinical Trial.
Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial.
Shitara K, Özgüroğlu M, Bang YJ, Di Bartolomeo M, Mandalà M, Ryu MH, Fornaro L, Olesiński T, Caglevic C, Chung HC, Muro K, Goekkurt E, Mansoor W, McDermott RS, Shacham-Shmueli E, Chen X, Mayo C, Kang SP, Ohtsu A, Fuchs CS; KEYNOTE-061 investigators. Shitara K, et al. Lancet. 2018 Jul 14;392(10142):123-133. doi: 10.1016/S0140-6736(18)31257-1. Epub 2018 Jun 4. Lancet. 2018. PMID: 29880231 Clinical Trial.
Mesoporous silica/organosilica nanoparticles for cancer immunotherapy.
Theivendran S, Lazarev S, Yu C. Theivendran S, et al. Among authors: lazarev s. Exploration (Beijing). 2023 May 9;3(3):20220086. doi: 10.1002/EXP.20220086. eCollection 2023 Jun. Exploration (Beijing). 2023. PMID: 37933387 Free PMC article. Review.
Proton and Heavy Particle Intracranial Radiosurgery.
Lehrer EJ, Prabhu AV, Sindhu KK, Lazarev S, Ruiz-Garcia H, Peterson JL, Beltran C, Furutani K, Schlesinger D, Sheehan JP, Trifiletti DM. Lehrer EJ, et al. Among authors: lazarev s. Biomedicines. 2021 Jan 3;9(1):31. doi: 10.3390/biomedicines9010031. Biomedicines. 2021. PMID: 33401613 Free PMC article. Review.
Integrated structure-based protein interface prediction.
Walder M, Edelstein E, Carroll M, Lazarev S, Fajardo JE, Fiser A, Viswanathan R. Walder M, et al. Among authors: lazarev s. BMC Bioinformatics. 2022 Jul 25;23(1):301. doi: 10.1186/s12859-022-04852-2. BMC Bioinformatics. 2022. PMID: 35879651 Free PMC article.
Late Miocene megalake regressions in Eurasia.
Palcu DV, Patina IS, Șandric I, Lazarev S, Vasiliev I, Stoica M, Krijgsman W. Palcu DV, et al. Among authors: lazarev s. Sci Rep. 2021 Jun 1;11(1):11471. doi: 10.1038/s41598-021-91001-z. Sci Rep. 2021. PMID: 34075146 Free PMC article.
174 results